🇺🇸 Rituximab Injection in United States

81 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Haemoglobin Decreased — 12 reports (14.81%)
  2. Platelet Count Decreased — 11 reports (13.58%)
  3. Febrile Neutropenia — 10 reports (12.35%)
  4. Haematocrit Decreased — 9 reports (11.11%)
  5. White Blood Cell Count Decreased — 9 reports (11.11%)
  6. Infection — 6 reports (7.41%)
  7. Lymphopenia — 6 reports (7.41%)
  8. Nausea — 6 reports (7.41%)
  9. Neutropenia — 6 reports (7.41%)
  10. Pyrexia — 6 reports (7.41%)

Source database →

Rituximab Injection in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Rituximab Injection approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Rituximab Injection in United States?

Hopital Foch is the originator. The local marketing authorisation holder may differ — check the official source linked above.